Full-Time
Updated on 3/13/2025
Medicines for healthspan extension via epigenetics
No salary listed
Senior
San Bruno, CA, USA
NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing on diseases related to aging, particularly in the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. Unlike competitors, NewLimit's approach is centered on epigenetic reprogramming, which could lead to a new class of medicines for age-related conditions. The goal is to significantly increase the duration of life spent in good health, serving healthcare markets including pharmaceutical companies and individual consumers.
Company Size
11-50
Company Stage
Series A
Total Funding
$38.9M
Headquarters
South San Francisco, California
Founded
2022
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Unlimited Paid Time Off
NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging
NewLimit aims to increase the number of healthy years each person lives by epigenetically reprogramming cells.
NewLimit, a startup that aspires to reverse aging by manipulating cells, announced on Tuesday that it’s raised $40 million in a Series A round from Kleiner Perkins and other venture firms, and from prominent individuals like former Google CEO Eric Schmidt and Y Combinator CEO Garry Tan.